⌕
Biocryst Pharmaceuticals · BCRX · Nasdaq
Tenet 73 · Solid
Compare
$7.61−0.91%At closeTenet 73 · Solid
$7.61−0.07 (−0.91%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Biocryst Pharmaceuticals (BCRX) Stock

Biocryst Pharmaceuticals (BCRX) closed at $7.61 on Nov 13, 2026; its Tenet Score is 73 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

27 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$7.61
Nov 13, 2026
Market cap
$2.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
6.23 – 11.22
low → high
Tenet Score
73/100
Solid · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Biocryst Pharmaceuticals Inc. scores 73/100. Solid. Strongest on growth and value versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
73/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
96
Quality
51
Health
50
Growth
96

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueAQualityCHealthCGrowthAMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
loss
P/B
—
neg_equity
P/S
2.0×
price to fiscal 2025 sales
ROE
—
neg_equity
Operating margin
39.0%
fiscal 2025, before interest and tax
Net margin
−37.4%
of revenue kept
Current ratio
2.71
current assets to liabilities
Net debt / EBITDA
—
no_ebitda
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVA…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 77 US ETFs · top wrappers by weightSee all ETFs holding BCRX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Biocryst Pharmaceuticals in?

Biocryst Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Biocryst Pharmaceuticals' Tenet Score?

Biocryst Pharmaceuticals' Tenet Score is 73 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.